Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $19.5800 (-2.1%) ($18.6500 - $20.1700) on Fri. Jul. 31, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.2% (three month average) | RSI | 37 | Latest Price | $19.5800(-2.1%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.5% a day on average for past five trading days. | Weekly Trend | TGTX declines -5.5% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(58%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.1% in a week (0% probabilities). VIXM(-35%) VXX(-32%) UUP(-18%) DRIV(-4%) XLC(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.1% (StdDev 6.2%) | Hourly BBV | 0 () | Intraday Trend | -2.3% | | | |
|
Resistance Level | $21.83 | 5 Day Moving Average | $20.14(-2.78%) | 10 Day Moving Average | $21(-6.76%) | 20 Day Moving Average | $21.83(-10.31%) | To recent high | -18.9% | To recent low | 73.9% | Market Cap | $2.48b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |